NCT00704106

Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders

HBV Viral Suppression by Entecavir in Adefovir Partial Responders

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 60 (actual)
• Sponsor: Pacific Health Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We propose a largely retrospective study with short-term prospective follow-up in a subgroup of patients who have not yet been treated with 48 weeks of entecavir following partial response to adefovir. The aim of the study is to describe sequential virologic response to adefovir and entecavir.

Detailed description

Amendment was made, and approved by WIRB in January 2009, to this protocol: We propose a largely retrospective study with short-term prospective follow-up in a subgroup of patients who have not yet been treated with 96 weeks of entecavir following adefovir treatment. The aim of the study is to describe sequential virologic response to adefovir and entecavir.

Conditions

• Hepatitis B

Interventions

Type	Name	Description
DRUG	Entecavir	0.5 or 1 mg dose qd

Timeline

• Start date: 2008-05-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2008-06-24
• Last updated: 2022-11-14

Locations

6 sites across 1 country: United States